Clinical trials: Anticoagulant
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot
The proposed PAUSE-2 RCT study is the logical next step to the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, which was completed on August 31, 2018.
- Trial name
- PAUSE2rctP (NCT04192552)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 3 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McMaster University
Atrial Fibrillation, Venous Thromboembolism
Warfarin Patient Self-management Implementation in the US Healthcare System
In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinic-directed warfarin management.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases
- Trial name
- NCT04766216
- Testing
- Patient self-management, Usual care provided by anticoagulation providers
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Utah
Atrial Fibrillation
Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation
To determine whether a comprehensive evaluation and customized multilevel educational interventions will increase the rate of use of oral anticoagulants and the adherence and persistence of use in patients with atrial…
- Trial name
- IMPACT-AF (NCT02082548)
- Testing
- Educational Intervention
- Where
- 5 sites in Argentina, Brazil and 3 more
- Volunteers
- 2,374 people
- Sponsor
- Duke University
Acute Major Bleeding
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate…
- Trial name
- NCT04867837
- Testing
- Octaplex
- Where
- 63 sites in United States, Austria and 11 more
- Volunteers
- 100 people
- Sponsor
- Octapharma
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Heparin-Induced Thrombocytopenia
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00673439
- Testing
- fondaparinux, warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Louisville
Ischemia, Anticoagulants
Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization
the Aim of the work is to compare the effect of CAT (Clopidogrel aspirin therapy) and AAT (Apixiban aspirin therapy) after lower extremity revascularization.
- Trial name
- CVAALR (NCT04168398)
- Testing
- Combination drug
- Where
- Egypt
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Atrial Fibrillation, Stroke
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
- Trial name
- NCT00262600
- Testing
- warfarin, Dabigatran dose 1, Dabigatran dose 2
- Where
- 984 sites in United States, Argentina and 42 more
- Volunteers
- 18,113 people
- Sponsor
- Boehringer Ingelheim
Polypharmacy, Insomnia
MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings
Scientific advances are constantly leading to better treatments. However, it is quite challenging for healthcare systems, including VA, to ask very busy providers to change the way they practice.
- Conditions
- Polypharmacy, Insomnia, Anticoagulants
- Trial name
- MIDAS cRCT (NCT05065502)
- Testing
- Academic Detailing (AD), LEAP
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Office of Research and Development
Antiphospholipid Syndrome
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
The antiphospholipid-antibody syndrome (APLA), which includes lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoproteinI antibodies, is a thrombophilic disorder associated with arterial thrombosis, venous thrombosis or…
- Trial name
- NCT00878137
- Testing
- INR by point-of-care instruments and venopuncture
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of North Carolina, Chapel Hill
Atrial Fibrillation
Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence of 1-2%. Without antithrombotic treatment, the annual risk of a cardioembolic event is 5-6%.
- Trial name
- PRAGUE-17 (NCT02426944)
- Testing
- NOAC, Left atrial appendage closure
- Where
- Czechia
- Volunteers
- 400 people
- Sponsor
- Charles University, Czech Republic
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Venous Thrombosis, Pulmonary Embolism
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
Blood clots in the leg veins, known as deep vein thrombosis, are important because they may travel to the lung (known as pulmonary embolism) and cause death. Blood clots are treated with blood thinners, or anticoagulants.
- Trial name
- NCT00186745
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Atrial Fibrillation
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention…
- Trial name
- FinACAF (NCT04645537)
- Volunteers
- 400,000 people
- Sponsor
- Helsinki University Central Hospital
Atrial Fibrillation, Coronary Artery Disease
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (>12 months) coronary stenting.
- Trial name
- OAC-ALONE (NCT01962545)
- Testing
- OAC alone
- Where
- Japan
- Volunteers
- 690 people
- Sponsor
- Satoshi Shizuta
Atrial Fibrillation and Flutter
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Background: The incidence of atrial fibrillation(AF) increases substantially with age and it is estimated that more than one third of AF patients are octogenarians.
- Trial name
- NCT02623049
- Testing
- New oral anticoagulant pharmacodynamic analysis (blood level assesment)
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Rabin Medical Center
Venous Thrombosis or Pulmonary Embolism
What Treatment for Patients With Phlebitis or Pulmonary Embolism ?
The objective of the "anticoagchoice" study is to analyze the preferences of people suffering from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt the medical prescriptions.
- Trial name
- AntiCoagChoice (NCT03889457)
- Testing
- anticoagulation choice
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Rennes University Hospital
Thrombophilia
Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal
Direct oral anticoagulants (DOAC) are anticoagulant molecules that act either directly on factor Xa (Apixaban, Rivaroxaban) or on factor IIa (Dabigatran).
- Trial name
- DOAC-Stop (NCT06171984)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in…
- Trial name
- NCT04234698
- Where
- Colombia
- Volunteers
- 2,076 people
- Sponsor
- Pfizer